Sclerostin and DKK1 in primary hyperparathyroidism

Area of Science:

• Endocrinology
• Bone Biology
• Molecular Signaling

Background:

• Bone formation is regulated by the Wnt pathway, antagonized by sclerostin and Dickkopf-1 (DKK1).
• Previous studies suggest altered sclerostin and DKK1 levels in conditions affecting bone metabolism, like osteoporosis and parathyroid disorders.

Purpose of the Study:

• To investigate mineral metabolism and Wnt pathway antagonists (sclerostin and DKK1) in postmenopausal women with primary hyperparathyroidism (PHPT).

Main Methods:

• Compared mineral metabolism markers, vitamin D levels, bone turnover markers (BAP, sCTX), serum sclerostin, and serum DKK1 in 21 postmenopausal women with PHPT and 42 age-matched healthy controls.
• Analyzed correlations between parathyroid hormone (PTH) and measured biochemical parameters.

Main Results:

• PHPT patients exhibited higher serum calcium and PTH, lower serum phosphates, lower 25-OH-vitamin D, and higher 1,25-dihydroxy-vitamin D compared to controls.
• Bone turnover markers (BAP, sCTX) were elevated in PHPT patients.
• Serum sclerostin was significantly lower (-26%) and serum DKK1 significantly higher (+57%) in PHPT patients versus controls.
• PTH positively correlated with 1,25-dihydroxy-vitamin D, BAP, sCTX, and DKK1, and negatively with 25-OH-vitamin D and sclerostin.

Conclusions:

• Postmenopausal women with PHPT show reduced serum sclerostin and elevated serum DKK1 levels.
• These alterations in Wnt pathway antagonists may contribute to the variable bone involvement observed in PHPT.
• Further research is needed to elucidate the interplay between sclerostin, DKK1, and bone status in PHPT.